Palmitoyl Hexapeptide-12
/ Synthetic palmitoylated hexapeptide; INCI 'Palmitoyl Hexapeptide-12'; elastin-stimulating cosmetic peptideALIAS · Biopeptide EL (trade) · Palmitoyl Hexapeptide-12 (INCI) · Pal-VGVAPG
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Cosmetic ingredient based on the VGVAPG elastin-derived hexapeptide. The base VGVAPG sequence is well-described in elastin biology as a chemotactic and matrix-modulatory fragment; the palmitoylated cosmetic form is documented mainly in supplier and trade literature.
VGVAPG is a hexapeptide derived from the repetitive hydrophobic domain of tropoelastin and is one of the best-characterised elastin-derived peptide ligands of the elastin-binding protein (EBP) and related receptors. The base peptide has chemotactic and proliferative effects on dermal fibroblasts in cell-culture models. Palmitoylation increases lipophilicity to support topical delivery; the cosmetic claim is elastin-fibre maintenance and matrix support.
Tier 4. The base VGVAPG sequence has substantial peer-reviewed literature in vascular biology and matrix biology; the cosmetic palmitoylated form (Palmitoyl Hexapeptide-12) is documented in supplier dossiers and finished-product trials rather than independent clinical-grade trials.
No published independent safety database for the cosmetic palmitoylated form. Cosmetic INCI status implies regulatory acceptance for topical use.
Regulatory status
- FDA status:
- Not FDA-approved
Inference from the VGVAPG matrix-biology literature to topical cosmetic efficacy is several conceptual steps removed — receptor engagement on cultured fibroblasts is not equivalent to clinically meaningful elastin restoration in aged skin.